03545nam 22006615 450 991089989870332120241024125745.03-031-71152-110.1007/978-3-031-71152-7(MiAaPQ)EBC31740245(Au-PeEL)EBL31740245(CKB)36393457000041(DE-He213)978-3-031-71152-7(EXLCZ)993639345700004120241024d2024 u| 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierEngineering Multi-Agent Systems 12th International Workshop, EMAS 2024, Auckland, New Zealand, May 6–7, 2024, Revised Selected Papers /edited by Daniela Briola, Rafael C. Cardoso, Brian Logan1st ed. 2024.Cham :Springer Nature Switzerland :Imprint: Springer,2024.1 online resource (204 pages)Lecture Notes in Artificial Intelligence,2945-9141 ;151523-031-71151-3 -- SPARKIT: A Mind Map-Based MAS for Idea Generation Support. -- Cooperative Multi-agent Approach for Automated Computer Game Testing. -- On the external concurrency of current BDI frameworks for MAS. -- SADMA: Scalable Asynchronous Distributed Multi-Agent Reinforcement Learning Training Framework. -- Synergizing Trust and Autonomy: Gaia-X Enabled Multi-Agent Ecosystems for Advanced Freight Fleet Management. -- Cognitive Planning for Persuasive Multimodal Interaction. -- A Novel Bidding Strategy for PDAs using MCTS in Continuous Action Spaces. -- Jadex BDI Agents Integrated with MATSim for Autonomous Mobility on Demand. -- Towards Engineering Explainable Autonomous Systems. -- Enhancing Confidence of the vGOAL Interpreter Using SAT Solving. -- Agents for DDD --- Back and Forth.This book constitutes the revised selected papers from the 12th International Workshop on Engineering Multi-Agent Systems, EMAS 2024, held in Auckland, New Zealand, during May 6–7, 2024. The 7 full papers and 4 short papers included in this book were carefully reviewed and selected from a total of 18 submissions. These papers focus on topics such as agent-oriented software engineering, programming multi-agent systems, declarative agent languages and technologies, artificial intelligence, and machine learning.Lecture Notes in Artificial Intelligence,2945-9141 ;15152Artificial intelligenceComputer engineeringComputer networksApplication softwareComputer scienceArtificial IntelligenceComputer Engineering and NetworksComputer and Information Systems ApplicationsTheory of ComputationArtificial intelligence.Computer engineering.Computer networks.Application software.Computer science.Artificial Intelligence.Computer Engineering and Networks.Computer and Information Systems Applications.Theory of Computation.006.3Briola Daniela1767682Cardoso Rafael C1314815Logan Brian1758369MiAaPQMiAaPQMiAaPQBOOK9910899898703321Engineering Multi-Agent Systems4213993UNINA03689nam 2200421z- 450 991034675660332120210211(CKB)4920000000094148(oapen)https://directory.doabooks.org/handle/20.500.12854/55785(oapen)doab55785(EXLCZ)99492000000009414820202102d2018 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierPathogenic Advances and Therapeutic Perspectives for Eosinophilic InflammationFrontiers Media SA20181 online resource (279 p.)Frontiers Research Topics2-88945-624-2 With the recent approval of the first eosinophil-depleting therapeutic agents targeting the IL-5 pathway for treatment of severe eosinophilic asthma, eosinophils and eosinophilic disorders are in the limelight. Indeed, setbacks during clinical development of these compounds have revealed how much remains to be known about eosinophil biology in vivo, and have nurtured profuse research both on basic eosinophil biology and on pathogenic disease mechanisms, in order to better delineate the most meaningful targets for innovative therapeutic strategies. On one hand, variable degrees of eosinophil depletion observed in some compartments during IL-5-targeted treatment indicate that certain eosinophil subsets may not rely on this cytokine and/or that other important pro-eosinophilic mediators and signaling pathways are operative in vivo. On the other hand, it is increasingly clear that disorders involving eosinophils such as asthma are the final outcome of complex interactions between diverse cell types and mediators, beyond eosinophils and IL-5. These include type 2 helper T (Th2) cells and innate lymphoid cells, mast cells, and a variety of factors that either activate eosinophils or are released by them. Although a considerable amount of research has focused on asthma because it is a common condition and because management of severe asthma remains a major challenge, several rare eosinophilic disorders with more homogenous features have proven to be extremely useful models to reach a better understanding of the involvement of eosinophils in tissue damage and dysfunction, and of the micro-environmental interactions operating within the complex network of eosinophilic inflammation. Unraveling this interplay has resulted in advances in the development of molecular tools to detect disease subsets and to monitor therapeutic responses, and in identification of promising new therapeutic targets. This Research Topic dedicated to eosinophilic conditions covers aspects of the biology of eosinophils and closely related cells of particular relevance for drug development, reports on translational research investigating pathogenic mechanisms of specific eosinophilic disorders in humans that will likely result in significant changes in the way patients are managed, and presents an overview of the current advancement of targeted drug development for these conditions, with a special focus on asthma.MedicinebicsscAsthmaEosinophil BiologyEosinophilic EsophagitisHypereosinophilic SyndromeILC2mast cellTh2 cellMedicineFlorence E. Roufosseauth1296324Mats W. JohanssonauthBOOK9910346756603321Pathogenic Advances and Therapeutic Perspectives for Eosinophilic Inflammation3024001UNINA